Educational Background: MD from University of Michigan
Research Interests: Dr. Feldman’s research interests lie in finding the optimal treatments to improve the response, survival rates, and quality of life in the treatment of lung and head and neck cancers. He is the UIC Principal Investigator on several studies that test the role of targeted agents in the treatment of lung and head and neck cancer. He is also interested in the application of large databases to answer critical clinical questions in the management of these malignancies.
Fun Facts: He is a “gym rat” and loves the game of basketball.
His father was a family practice physician and used to make house calls.
He and his wife have 2 grown sons and 2 dogs (cocker spaniels).
March 19, 2017: Each month, the Big Ten Cancer Research Consortium highlights advances in research and treatment led by our member institutions. Get up to date on the latest discoveries and breakthroughs from Across the Consortium!Read More
March 11, 2017: March is the time to take stock of the number two ranking cause of cancer deaths in the United States: colorectal cancer (cancer of the colon or rectum). Since this time last year, it is estimated that 140,000 Americans were diagnosed with colorectal cancer, and more than 50,000 people died from it. During Colorectal Cancer Awareness Month, researchers, clinicians, survivors, and patients unite with the common purpose of discovering hope for those facing this cancer. Read More
March 3, 2017: Triple negative breast cancer (TNBC) represents a relatively small proportion — 15 percent — of all breast cancers. Yet a great deal of attention has been given to TNBC in recent years. While targeted therapies have been developed for breast cancers expressing estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, advances in TNBC have been hampered by a lack of identified targets for the disease. As a result, the only approved treatment for TNBC remains chemotherapy. Recent discoveries, however, have identified several molecular subtypes of TNBC, and researchers are now developing clinical trials to explore potential ways to treat these subtypes. A new Big Ten Cancer Research Consortium study, led by Ruth O’Regan, MD (pictured), of the University of... Read More
March 1, 2017:Investigator Spotlight Mark Stein, MD Educational Background: BS, Yale; MD, New York Medical College; Internal Medicine, Albert Einstein; Fellowship in Oncology Hematology, Mount Sinai School of Medicine Rutgers Cancer Institute of New Jersey. 1/13/17 Photo by John O'Boyle Research Interests: I am interested in developing novel therapies for the treatment of genitourinary malignancies. The potential benefit of immunotherapy for the treatment of prostate cancer is still poorly understood. Through collaboration’s with my colleagues at Rutgers, pharmaceutical companies (some of which are even located in New Jersey) and other members of the Big Ten, it is my hope that we will be able to utilize immunotherapy earlier in the course of treatment of prostate cancer and... Read More
Feb. 21, 2017: For more than 25 years, Lawrence Feldman, MD, has been researching and treating patients with lung and head and neck cancers. In all those years, there have been few times that rival the optimism he feels when he considers the recent discoveries and advances in cancer immunotherapy. “Over the last couple of years, immuno-oncology has been very successful in both lung and head and neck cancer. It’s been a very exciting area,” Dr. Feldman, a researcher at the University of Illinois at Chicago, said. The approval of the PD-1 checkpoint inhibitor pembrolizumab (Keytruda®) by the U.S. Food and Drug Administration, first in advanced melanoma, and more recently in advanced non-small cell lung cancer and head and neck cancer, has accelerated progress in the fight against cancer. Pembrolizumab... Read More
Feb. 19, 2017: Just out of the starting blocks of 2017, the Big Ten Cancer Centers are already vaulting over more than $30 million of impressive grants, awards, and gifts, long jumping into new leadership positions and appointments, and crossing the finish line of multiple pace-setting studies. In this month's edition of Across the Consortium, we recap recent highlights of this winning relay team, the Big Ten CRC! Read More
Feb. 9, 2017 The University of Illinois at Chicago has named Oana Danciu, MD, its representative to the Big Ten Cancer Research Consortium Steering Committee. Dr. Danciu is assistant professor of medicine in the Division of Hematology and Oncology at UIC, and serves as interim director of UIC’s Clinical Trials Office. She specializes in the treatment of patients with breast cancer. Her research interests include development of clinical trials using experimental therapeutics. She is working on identifying molecular pathways and predictive biomarkers for different subtypes of breast cancer. Dr. Danciu received her medical degree from Carol Davila University in Bucharest,... Read More
Feb. 4, 2017: Whether a basic scientist is driven to the clinic to share discoveries or a clinician is driven to the lab in search of answers, frontiers in oncology traverse two worlds: the lab and the clinic. Some researchers, like Sheldon L. Holder, MD, PhD, of the Penn State Cancer Institute, a member of the Big Ten Cancer Research Consortium, embody the best of both worlds. Through bold curiosity, teamwork, and an interdisciplinary perspective that not only solves problems, but does so with purpose, Holder exemplifies the Big Ten CRC’s commitment to engaging basic scientists in the development of clinical trials. An empowered curiosity Holder grew up on the Island of Bermuda, where his interest in medicine was sparked. “It began very early, almost as far back as I can remember. In second grade I... Read More
Jan. 23, 2017: The Big Ten Cancer Research Consortium's “Across the Consortium” is your all-access pass to the latest action in cancer research conducted by our member institutions. We begin a new year with recent highlights from each member institution. Here’s to a promising new year across the consortium! Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube